Skip to main content
Premium Trial:

Request an Annual Quote

Singlera Genomics, Yale Partner on NIPT Clinical Trial

NEW YORK (GenomeWeb) – Noninvasive prenatal testing startup Singlera Genomics has partnered on a clinical trial with researchers at Yale University to evaluate Singlera's technology for noninvasive prenatal testing of chromosomal aneuploidy and fetal DNA fraction measurement.

Yuan Gao from Johns Hopkins University and Kun Zhang from the University of California, San Diego cofounded La Jolla, California-based Singlera in June 2014. The company has exclusively licensed several technologies developed in Zhang's UCSD laboratory for its proprietary NIPT, which has a turnaround time of one to two days, the company said.

Researchers from Yale, led by Michael Paidas, professor and vice chair of obstetrics, will evaluate Singlera's test in a clinical trial. According to the company, an advantage of the test compared to other NIPTs is that it simultaneously measures fetal DNA fraction, which has been observed to be lower in women with a higher body mass index.

"Having a reliable screen for patients with increased body mass index would be transformative and significantly decrease invasive testing in this population," Paidas said in a statement. 

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.